Prognostic role of nucleophosmin in colorectal carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 5, 2014, Pages 2021-2026

  Yang, Yu Feng ^a   Zhang, Xi Ying ^a   Yang, Mei ^a   He, Ze Hua ^b   Peng, Ning Fu ^b   Xie, Shu Rui ^a   Xie, Yan Fang ^a  

^a Dongguan ShiLong People's Hospital   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal carcinomas; Nucleophosmin; Prognosis

Indexed keywords

NUCLEAR PROTEIN; NUCLEOPHOSMIN; TUMOR MARKER;

CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; UPREGULATION;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84899045073     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.5.2021     Document Type: Article

References (43)

1. Bertwistle D, Sugimoto M, Sherr CJ (2004). Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol, 24, 985-96.
2. Choi HJ, Jung IK, Kim SS, et al (1997). Proliferating cell nuclear antigen expression and its relationship to malignancy potential in invasive colorectal carcinomas. Dis Colon Rectum, 40, 51-9.
3. Cilloni D, Messa F, Rosso V, et al (2008). Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia, 22, 1234-40.
4. Colombo E, Marine JC, Danovi D, et al (2002). Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol, 4, 529-33.
5. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, et al (2010). Nucleophosmin, p53, and Ki-67 expression patterns on an oral squamous cell carcinoma tissue microarray. Hum Pathol, 41, 1079-86.
6. Evans C, Morrison J, Heriot AG, et al (2006). The correlation between colorectal cancer rates of proliferation and apoptosis and systemic levels plus their influence upon survival. Br J Cancer, 94, 1412-9.
7. Feuerstein N, Chan PK, Mond JJ (1988). Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23. Implication for the role of the nucleolus in early transduction of mitogenic signals. J Biol Chem, 263, 10608-12.
8. Feuerstein N, Spiegel S, Mond JJ (1998). The nuclear matrix protein, numatrin (B23), is associated with growth factorinduced mitogenesis in Swiss 3T3 fibroblasts and with T lymphocyte proliferation stimulated by lectins and anti-T cell antigen receptor antibody. J Cell Biol, 107, 1629-42.
9. Fodor IK, Hutchins GG, Espiritu C, et al (2012). Prognostic and predictive significance of proliferation in 867 colorectal cancers. J Clin Pathol, 65, 989-95.
10. Grisendi S, Mecucci C, Falini B, et al (2006). Nucleophosmin and cancer. Nat Rev Cancer, 6, 493-505.
11. Guzinska-Ustymowicz K, Pryczynicz A, Kemona A, et al (2009). Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Anticancer Res, 29, 3049-52.
12. Guzinska-Ustymowicz K, Stepien E, Kemona A (2008). MCM-2, Ki-67 and PCNA Protein Expressions in pT3G2 Colorectal Cancer Indicated Lymph Node Involvement. Anticancer Res, 28, 451-7.
13. Herrera JE, Savkur R, Olson MO (1995). The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res, 23, 3974-9.
14. Jeong EG, Lee SH, Yoo NJ, et al (2007). Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers. APMIS, 115, 341-6.
15. Karhemo PR, Rivinoja A, Lundin J, et al (2011). An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast Cancer. Am J Pathol, 179, 1004-14.
16. Kikuta K, Tochigi N, Shimoda T, et al (2009). Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin Cancer Res, 15, 2885-94.
17. Kurki S, Peltonen K, Laiho M (2004). Nucleophosmin. HDM2 and p53: players in UV damage incited nucleolar stress response. Cell Cycle, 3, 976-9.
18. Liu WH, Yung BY (1998). Mortalization of human promyelocytic leukemia HL-60 cells to be more susceptible to sodium butyrate-induced apoptosis and inhibition of telomerase activity by down-regulation of nucleophosmin/B23. Oncogene, 17, 3055-64.
19. Liu X, Liu Z, Jang SW, et al (2007). Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival. Proc Natl Acad Sci USA, 104, 9679-84.
20. Liu Y, Zhang F, Zhang XF, et al (2012). Expression of Nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells. J Biomed Sci, 19, 53.
21. Mukda E, Pintaraks K, Sawangpanich R, et al (2011). FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia. Asian Pac J Cancer Prev, 12, 1827-31.
22. Nakae S, Nakamura T, Ikegawa R, et al (1998). Evaluation of argyrophilic nucleolar organizer region and proliferating cell nuclear antigen in colorectal cancer. J Surg Oncol, 69, 28-35.
23. Nozawa Y, Van Belzen N, Van der Made AC, et al (1996). Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol, 178, 48-52.
24. Okuda M (2002). The role of nucleophosmin in centrosome duplication. Oncogene, 21, 6170-4.
25. Okuda M, Horn HF, Tarapore P, et al (2000). Nucleophosmin/ B23 is a target of CDK2/cyclin E in centrosome duplication. Cell, 103, 127-40.
26. Okuwaki M, Matsumoto K, Tsujimoto M, et al (2001). Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett, 506, 272-6.
27. Oshima CT, Iriya K, and Forones NM (2005). Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma, 52, 420-4.
28. Pianta A, Puppin C, Franzoni A, et al (2010). Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun, 397, 499-504.
29. Salminen E, Palmu S, Vahlberg T, et al (2005). Increased prolferation activity measured by immunoreactive Ki-67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol, 11, 3245-9.
30. Sato K, Hayami R, Wu W, et al (2004). Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. J Biol Chem, 279, 30919-22.
31. Savkur RS, Olson MO (1998). Preferential cleavage in preribosomal RNA by protein B23 endoribonuclease. Nucleic Acids Res, 26, 4508-15.
32. Shahab S, Shamsi TS, Ahmed N (2013). Prognostic involvement of nucleophosmin mutations in acute myeloid leaukemia. Asian Pac J Cancer Prev, 14, 5615-20.
33. Shields LB, Gerçel-Taylor C, Yashar CM, et al (1997). Induction of immune responses to ovarian tumor antigens by multiparity. J Soc Gynecol Investig, 4, 298-304.
34. Sportoletti P, Grisendi S, Majid SM, et al (2008). Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood, 111, 3859-62.
35. Subong EN, Shue MJ, Epstein JI, et al (1999). Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4- 216) recognizes nucleophosmin/B23. Prostate, 39, 298-304.
36. Swaminathan V, Kishore AH, Febitha KK, et al (2005). Human histone chaperone nucleophosmin enhances acetylationdependent chromatin transcription. Mol Cell Biol, 25, 7534-45.
37. Tanaka M, Omura K, Watanabe Y, et al (1994). Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol, 57, 57-64.
38. Tanaka M, Sasaki H, Kino I, et al (1992). Genes preferentially expressed in embryo stomach are predominantly expressed in gastric cancer. Cancer Res, 52, 3372-7.
39. Tsui KH, Cheng AJ, Chang PL, et al (2004). Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology, 64, 839-44.
40. Tsui KH, Juang HH, Lee TH, et al (2008). Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacol Sin, 29, 364-70.
41. Wong JC, Hasan MR, Rahman M, et al (2013). Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence. Int J Cancer, 133, 1567-77.
42. Xu AG, Yu ZJ, Jiang B, et al (2010). Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol, 16, 960-5.
43. Yun JP, Miao J, Chen GG, et al (2007). Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br J Cancer, 96, 477-84.